( a ) excludes discontinued operations .
( b ) earnings before interest expense and taxes as a percent of average total assets .
( c ) total debt as a percent of the sum of total debt , shareholders 2019 equity and non-current deferred income tax liabilities .
the results above include the impact of the specified items detailed below .
additional discussion regarding the specified items in fiscal years 2017 , 2016 and 2015 are provided in item 7 .
management 2019s discussion and analysis of financial condition and results of operations. .

Years Ended September 30
Millions of dollars, except per share amounts
2017
2016
2015
2014
2013
Total specified items
$1,466
$1,261
$1,186
$153
$442
After-tax impact of specified items
$971
$892
$786
$101
$279
Impact of specified items on diluted earnings per share
$(4.34)
$(4.10)
$(3.79)
$(0.51)
$(1.40)
Impact of dilution from share issuances
$(0.54)
$—
$(0.02)
$—
$—

item 7 .
management 2019s discussion and analysis of financial condition and results of operations the following commentary should be read in conjunction with the consolidated financial statements and accompanying notes .
within the tables presented throughout this discussion , certain columns may not add due to the use of rounded numbers for disclosure purposes .
percentages and earnings per share amounts presented are calculated from the underlying amounts .
references to years throughout this discussion relate to our fiscal years , which end on september 30 .
company overview description of the company and business segments becton , dickinson and company ( 201cbd 201d ) is a global medical technology company engaged in the development , manufacture and sale of a broad range of medical supplies , devices , laboratory equipment and diagnostic products used by healthcare institutions , life science researchers , clinical laboratories , the pharmaceutical industry and the general public .
the company's organizational structure is based upon two principal business segments , bd medical ( 201cmedical 201d ) and bd life sciences ( 201clife sciences 201d ) .
bd 2019s products are manufactured and sold worldwide .
our products are marketed in the united states and internationally through independent distribution channels and directly to end-users by bd and independent sales representatives .
we organize our operations outside the united states as follows : europe ; ema ( which includes the commonwealth of independent states , the middle east and africa ) ; greater asia ( which includes japan and asia pacific ) ; latin america ( which includes mexico , central america , the caribbean , and south america ) ; and canada .
we continue to pursue growth opportunities in emerging markets , which include the following geographic regions : eastern europe , the middle east , africa , latin america and certain countries within asia pacific .
we are primarily focused on certain countries whose healthcare systems are expanding , in particular , china and india .
strategic objectives bd remains focused on delivering sustainable growth and shareholder value , while making appropriate investments for the future .
bd management operates the business consistent with the following core strategies : 2022 to increase revenue growth by focusing on our core products , services and solutions that deliver greater benefits to patients , healthcare workers and researchers; .

Question: Analyse this data from a financial earnings document. what is the range of after-tax impact of specified items from 2013-2017 , in millions?
Choices:
870.0
870
-870
29
974.8
Correct choice index: 0